View Item 

Show simple item record

Osteonecrosis of the Maxilla and Mandible in Patients with Advanced Cancer Treated with Bisphosphonate Therapy
dc.contributor.authorEstilo, Cherry L.
dc.contributor.authorVan Poznak, Catherine H.
dc.contributor.authorWiliams, Tijaana
dc.contributor.authorBohle, George C.
dc.contributor.authorLwin, Phyu T.
dc.contributor.authorZhou, Qin
dc.contributor.authorRiedel, Elyn R.
dc.contributor.authorCarlson, Diane L.
dc.contributor.authorSchoder, Heiko
dc.contributor.authorFarooki, Azeez
dc.contributor.authorFornier, Monica
dc.contributor.authorHalpern, Jerry L.
dc.contributor.authorTunick, Steven J.
dc.contributor.authorHuryn, Joseph M.
dc.date.accessioned2017-12-15T16:47:20Z
dc.date.available2017-12-15T16:47:20Z
dc.date.issued2008-08
dc.identifier.citationEstilo, Cherry L.; Van Poznak, Catherine H.; Wiliams, Tijaana; Bohle, George C.; Lwin, Phyu T.; Zhou, Qin; Riedel, Elyn R.; Carlson, Diane L.; Schoder, Heiko; Farooki, Azeez; Fornier, Monica; Halpern, Jerry L.; Tunick, Steven J.; Huryn, Joseph M. (2008). "Osteonecrosis of the Maxilla and Mandible in Patients with Advanced Cancer Treated with Bisphosphonate Therapy." The Oncologist 13(8): 911-920.
dc.identifier.issn1083-7159
dc.identifier.issn1549-490X
dc.identifier.urihttps://hdl.handle.net/2027.42/139939
dc.publisherAlphaMed Press
dc.publisherWiley Periodicals, Inc.
dc.subject.otherOsteonecrosis of the jaw
dc.subject.otherBisphosphonate therapy
dc.subject.otherZoledronic acid
dc.subject.otherPamidronate
dc.titleOsteonecrosis of the Maxilla and Mandible in Patients with Advanced Cancer Treated with Bisphosphonate Therapy
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelHematology and Oncology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.contributor.affiliationumDepartment of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA
dc.contributor.affiliationotherDental Service, Department of Surgery,
dc.contributor.affiliationotherBreast Cancer Medicine Service, Department of Medicine, Memorial Sloan‐Kettering Cancer Center, New York, New York, USA;
dc.contributor.affiliationotherEndocrinology Service, Department of Medicine, and
dc.contributor.affiliationotherNuclear Medicine Service, Department of Radiology,
dc.contributor.affiliationotherSurgical Pathology Service, Department of Pathology,
dc.contributor.affiliationotherDepartment of Epidemiology and Biostatistics,
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139939/1/onco0911.pdf
dc.identifier.doi10.1634/theoncologist.2008-0091
dc.identifier.sourceThe Oncologist
dc.identifier.citedreferenceGreen JR, Preclinical pharmacology of zoledronic acid. Semin Oncol. 2002; 29 suppl 21: 3 – 11
dc.identifier.citedreferenceColeman RE, Skeletal complications of malignancy. Cancer. 1997; 80 suppl 8: 1588 – 1594
dc.identifier.citedreferenceBody JJ, Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer. 2003; 97 suppl 3: 859 – 865
dc.identifier.citedreferenceBagan JV, Murillo J, Jimenez Y, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: Series of 10 cases. J Oral Pathol Med. 2005; 34: 120 – 123
dc.identifier.citedreferenceCarter GD, Goss AN, Bisphosphonates and avascular necrosis of the jaws. Aust Dent J. 2003; 48: 268
dc.identifier.citedreferenceDurie BGM, Katz M, McCoy J, et al. Osteonecrosis of the jaws in myeloma: Time dependent correlation with Aredia® and Zometa® use. Blood. 2004; 104: 756
dc.identifier.citedreferenceEstilo CL, Van Poznak CH, Williams T, et al. Osteonecrosis of the maxilla and mandible in patients treated with bisphosphonates: A retrospective study. J Clin Oncol. 2004; 22: 8088a
dc.identifier.citedreferenceMarx RE, Pamidronate (Aredia®) and zoledronate (Zometa®) induced avascular necrosis of the jaws: A growing epidemic [letter]. J Oral Maxillofac Surg. 2003; 61: 1115 – 1117
dc.identifier.citedreferenceVan Poznak C, Estilo C, Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates. Oncology (Williston Park). 2006; 20: 1053 – 1062, discussion 1065–1066
dc.identifier.citedreferenceRuggiero SL, Fantasia J, Carlson E, Bisphosphonate‐related osteonecrosis of the jaw: Background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006; 102: 433 – 441
dc.identifier.citedreferenceHoff AO, Toth BB, Altundag K, et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol. 2006; 24: 8528a
dc.identifier.citedreferenceDurie BG, Katz M, Crowley J, Osteonecrosis of the jaw and bisphosphonates [letter]. N Engl J Med. 2005; 353: 99 – 102
dc.identifier.citedreferenceBamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol. 2005; 23: 8580 – 8587
dc.identifier.citedreferenceAssouline‐Dayan Y, Chang C, Greenspan A, et al. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. 2002; 32: 94 – 124
dc.identifier.citedreferenceHansen T, Kunkel M, Springer E, et al. Actinomycosis of the jaws—histopathological study of 45 patients shows significant involvement in bisphosphonate‐associated osteonecrosis and infected osteoradionecrosis. Virchows Arch. 2007; 451: 1009 – 1017
dc.identifier.citedreferenceRuggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg. 2004; 62: 527 – 534
dc.identifier.citedreferenceMigliorati CA, Schubert MM, Peterson DE, et al. Bisphosphonate‐associated osteonecrosis of mandibular and maxillary bone: An emerging oral complication of supportive cancer therapy. Cancer. 2005; 104: 83 – 93
dc.identifier.citedreferenceAmerican Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: Expert panel recommendations. J Am Dent Assoc. 2006; 137: 1144 – 1150
dc.identifier.citedreferenceMarx RE, Sawatari Y, Fortin M, et al. Bisphosphonate‐induced exposed bone (osteonecrosis/osteoporosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005; 63: 1567 – 1575
dc.identifier.citedreferenceO’Connor, Padmanabhan A, Wilding G, et al. Bisphosphonate‐induced osteonecrosis of the jaw: Risk factors and diagnostic utility of bone scans. J Clin Oncol. 2007; 25 suppl 20: 9052
dc.identifier.citedreferenceChiandussi S, Biasotto M, Dore F, et al. Clinical and diagnostic imaging of bisphosphonate‐associated osteonecrosis of the jaws. Dentomaxillofac Radiol. 2006; 35: 236 – 243
dc.identifier.citedreferenceBoissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000; 60: 2949 – 2954
dc.identifier.citedreferenceCroucher PI, De Hendrik R, Perry MJ, et al. Zoledronic acid treatment of 5T2MM‐bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res. 2003; 18: 482 – 492
dc.identifier.citedreferenceFournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone‐stimulated vascular regrowth in ventral prostate in castrated rats. Cancer Res. 2002; 62: 6538 – 6544
dc.identifier.citedreferenceWood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002; 302: 1055 – 1061
dc.identifier.citedreferenceHanahan D, Weinberg RA, The hallmarks of cancer. Cell. 2000; 100: 57 – 70
dc.identifier.citedreferenceBauer SM, Bauer RJ, Velazquez OC, Angiogenesis, vasculogenesis, and induction of healing in chronic wounds. Vasc Endovascular Surg. 2005; 39: 293 – 306
dc.identifier.citedreferenceGerber HP, Ferrara N, Angiogenesis and bone growth. Trends Cardiovasc Med. 2000; 10: 223 – 228
dc.identifier.citedreferenceAragon‐Ching JB, Ning YM, Latham L, et al. Osteonecrosis of the jaw (ONJ) in androgen‐independent prostate cancer (AIPC) patients receiving ATTP (bevacizumab, docetaxel, thalidomide and prednisone). J Clin Oncol. 2007; 25: 19594a
dc.identifier.citedreferenceWeitzman R, Sauter N, Eriksen EF, et al. Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients—May 2006. Crit Rev Oncol Hematol. 2007; 62: 148 – 152
dc.identifier.citedreferenceKhosla S, Burr D, Cauley J, et al. Bisphosphonate‐associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22: 1479 – 1491
dc.identifier.citedreferenceAdvisory Task Force on Bisphosphonate‐Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate‐related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007; 65: 369 – 376
dc.identifier.citedreferenceMigliorati CA, Casiglia J, Epstein J, et al. Managing the care of patients with bisphosphonate‐associated osteonecrosis: An American Academy of Oral Medicine position paper. J Am Dent Assoc. 2005; 136: 1658 – 1668
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
onco0911.pdf
Size:
643.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.